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Abstract—Antioxidant vitamins C and E have protective properties in genetic hypertension associated with enhanced
oxidative stress. This study investigated whether vitamins C and/or E modulate vascular function by regulating
enzymatic activities of endothelial nitric oxide synthase (eNOS) and NAD(P)H oxidase using thoracic aortas of 20- to
22-week-old male spontaneously hypertensive rats (SHR) and their matched normotensive counterparts, Wistar-Kyoto
rats (WKY). SHR aortas had impaired relaxant responses to acetylcholine but not to sodium nitroprusside, despite an
2-fold increase in eNOS activity and NO release. The levels of superoxide anion (O2), a potent NO scavenger, and
NAD(P)H oxidase activity were also 2-fold higher in SHR aortas. Mechanical but not pharmacological inactivation of
endothelium (by rubbing and 100 mol/L L-NAME, respectively) significantly abrogated O2 in both strains.
Treatments of SHR aortas with NAD(P)H oxidase inhibitors, namely diphenyleneiodinium and apocynin, significantly
diminished O2 production. The incubation of SHR aortas with different concentrations of vitamin C (10 to 100 mol/L)
and specifically with high concentrations of vitamin E (100 mol/L) improved endothelial function, reduced superoxide
production as well as NAD(P)H oxidase activity, and increased eNOS activity and NO generation in SHR aortas to the
levels observed in vitamin C- and E-treated WKY aortas. Our results reveal endothelial NAD(P)H oxidase as the major
source of vascular O2 in SHR and also show that vitamins C and E are critical in normalizing genetic endothelial
dysfunction through regulation of eNOS and NAD(P)H oxidase activities. (Hypertension. 2003;41:534-539.)
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The endothelium plays pivotal roles in the maintenance ofvascular tone and blood pressure by regulating the
release of several vasoactive substances, including nitric
oxide (NO).1 However, its characteristics change in patho-
logical conditions leading to a phenomenon called “endothe-
lial dysfunction,” which is characterized by impaired endo-
thelium-dependent relaxation. Endothelial dysfunction has
been reported in conduit and resistance arteries of both
essential hypertensive patients2,3 and various animal models
of essential hypertension.4,5
Current data as to the pathogenesis of hypertensive endo-
thelial dysfunction are extremely diverse. Diminished pro-
duction of NO caused by either inefficient utilization of
substrate L-arginine6 or impaired expression/activity of endo-
thelial NO synthase (eNOS)7 and impaired endothelium-
derived hyperpolarizing factor–mediated hyperpolarization of
resistance vessels have been implicated in this process.8
However, a single unifying mechanism has yet to emerge.
NO, generated within vascular endothelium by eNOS, is
considered the most important endothelium-derived vasodi-
lator in conduit arteries. Although eNOS is constitutively
expressed, many pathophysiological stimuli may regulate its
expression. Indeed, sex hormones9 elicit an increase in eNOS
gene expression, whereas hypoxia10 downregulates its expres-
sion. The current data on the molecular regulation of eNOS in
the cardiovascular system in essential hypertension are rather
conflicting. Increased,11 decreased,12 and unaltered13 levels of
eNOS expression have thus far been reported in SHR.
In recent years, exaggerated vascular production of reac-
tive oxygen species (ROS), in particular O2 by NAD(P)H
oxidase and/or uncoupled state of eNOS as a result of its
activation at suboptimal concentrations of its cofactor tetra-
hydrobiopterin (H4B) or diminished metabolism of ROS by
antioxidant enzymes or impaired regeneration of reduced
antioxidants, has been associated with the pathogenesis of
this phenomenon in hypercholesterolemia14 and stroke prone
SHR (SHRSP).15
ROS modulate vascular function by scavenging NO and
producing peroxynitrite (OONO) in the process. OONO,
another ROS, oxidizes proteins and elicits both breakage in
DNA structure and shortage of intracellular antioxidants such
as glutathione and cysteine. ROS are also involved in the
oxidative modification of LDL.1
Several recent studies have shown the beneficial effects of
treatments with antioxidants such as allopurinol and hy-
drosoluble coenzyme Q10 in patients with diabetes mellitus
and insulin-resistant hypertension, respectively.16,17 An accu-
mulating body of evidence has also demonstrated that anti-
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oxidant vitamins C and E are also implicated in the improve-
ment of endothelial function in human subjects and in animal
models of human diseases including hypertension.18–20 In-
deed, vitamin C alone or in combination with vitamin E has
been shown to enhance NO generation and reduce blood
pressure in hypertensive animals.21 Moreover, dietary supple-
mentation of vitamin E has been shown to enhance total
antioxidant status and reduce blood pressure in SHR.18,22
Although both antioxidant vitamins are known to stimulate
NO generation in endothelial cells and have ROS-scavenging
effects, the underlying mechanisms of action are
unknown.22,23
The purpose of the present study was therefore to investi-
gate whether vitamins C and E improve endothelial function
in SHR aortas by alteration of the redox state through
regulation of the enzymatic activities of eNOS and NAD(P)H
oxidase and therefore release of NO and O2, respectively.
Methods
Animals and Thoracic Aorta Preparation
The studies were performed with thoracic aortas obtained from 20-
to 22-week-old male SHR and their age- and gender-matched
normotensive counterparts, Wistar-Kyoto rats (WKY). Thoracic
aortas were removed from anticoagulated rats (100 U heparin IV)
under deep sodium pentobarbitol anesthesia (100 mg/kg body IP)
and carefully cleaned of adhering tissue. The aortas were then either
cut into 4 transverse rings (3 to 5 mm in length) for vascular
reactivity experiments or were washed with PBS under a tissue
culture hood and bisected longitudinally before placing into cell
culture flasks. The aortas were incubated in medium 199 containing
10% fetal calf serum, 10% newborn calf serum, 250 U/mL penicillin,
250 g/mL streptomycin, 12.5 g/mL amphotericin B, 50 g/mL
gentamicin, and different concentrations (10 to 100 mol/L) of
vitamins C (L-ascorbic acid, Sigma) or E (Ephynal; injectable form
of -tocopherol acetate at the concentration of 100 mg/2 mL,
Roche). All other reagents were purchased from Gibco BRL. Flasks
that did not contain vitamins served as controls. After 24 hours,
media were removed; the tissues were washed with PBS and
homogenized before measurements of enzyme activities and NO or
O2 levels.
All investigations were performed in accordance with the UK
“Home Office Guidance on the Operation of the Animals (Scientific
Procedures) Act 1986.”
Vascular Reactivity Studies
Rings were equilibrated for 90 minutes under 2 g resting tension in
organ baths filled with Krebs buffer [in (mmol/L): NaCl 118.3, KCl
4.7, MgSO4 1.2, KH2PO4 1.22, CaCl2 2.5, NaHCO3 25, glucose 11.1,
pH 7.4] and constantly gassed with carbogen (95% O2 /5% CO2).
Changes in isometric tension were detected and recorded by a force
transducer and an 8-channel transducer data acquisition system
(LE-TR201 and PowerLab/8S, ADInstruments), respectively.
After the initial equilibration period, ordinary Krebs solution was
replaced with fresh solution containing 1 mol/L indomethacin to
dismiss the relaxant effects of prostanoids. All experiments were
performed in the latter solution.
At the beginning of each experiment, dose-response curves to
phenylephrine (PE, 0.003 to 10 mol/L) were obtained. Rings were
then washed and equilibrated before contraction with submaximal
concentration of PE before detection of endothelium-dependent and
endothelium-independent relaxant responses to acetylcholine (ACh,
0.03 to 10 mol/L) or sodium nitroprusside (SNP, 0.01 to 10
mol/L), respectively. Only one vasorelaxant agent was used on
each ring.
This experimental pattern was repeated for the studies in which
either vitamin C or E was added to organ baths for 20 minutes before
investigation of relaxant responses to ACh.
Measurement of NOS Activity
NOS activity was measured by the conversion of L-[3H]-arginine
to L-[3H]-citrulline. Briefly, isolated aortic rings were homoge-
nized, on ice, in TRIS buffer (50 mmol/L, pH 7.4) containing
leupeptin (0.2 mol/L), pepstatin A (1.5 mmol/L), and phenyl-
methylsulfonyl fluoride (PMSF, 1 mmol/L). Samples were incu-
bated at 37°C for 30 minutes in the presence of calmodulin (30
nmol/L), NADPH (1 mmol/L), H4B (5 mol/L), Ca2 (2 mmol/L),
L-valine (50 mmol/L), and a mixture of unlabeled (0 to 5 mol/L)
and L-[3H]-arginine (10 mmol/L) (Amersham Pharmacia). To
assess the contribution of iNOS (calcium-independent isoform) to
overall NOS activity, Ca2 was replaced with EGTA (1 mmol/L).
Reactions were terminated by the addition of 1 mL HEPES
(20 mmol/L, pH 5.5) containing EDTA (1 mmol/L) and EGTA
(1 mmol/L). Newly formed L-[3H]citrulline, neutral at pH 5.5,
was separated from the incubation mixture by cation exchange
resin (Dowex AG 50 W-X8, Bio-Rad) and quantified by a liquid
scintillation counter. Results were expressed as picomoles of
L-citrulline per milligram of protein per minute.
Nitrite Detection
Nitrite levels were measured in aortic homogenates by Griess
reaction as index of NO generation after conversion of nitrate to
nitrite by nitrate dehydrogenase.24 An aliquot of the supernatant was
mixed with an equal volume of Griess reagent (sulfanilamide, 1%
wt/vol; naphthylethylenediamine dihydrochloride, 0.1% wt/vol; and
orthophosphoric acid, 2.5% vol/vol) and incubated at room temper-
ature for 10 minutes. The absorbance of the samples was determined
at 540 nm wavelength and compared with those of known concen-
trations of sodium nitrite. The amount of nitrite formed was
normalized to the protein content of the respective aorta.
NADH/NADPH Oxidase Activity
Aortic homogenates were prepared on ice in lysis buffer containing
1 mmol/L EGTA, 20 mmol/L monobasic potassium phosphate (pH
7.0), 0.5 g/mL leupeptin, 0.7 g/mL pepstatin, 10 g/mL aprotinin,
and 0.5 mmol/L PMSF. Oxidase activity was measured by lucigenin-
enhanced chemiluminescent detection of superoxide in a luminom-
eter. The reaction was initiated by the addition of 200 g of total
protein to reaction buffer containing 1 mmol/L EGTA, 150 mmol/L
sucrose, 5 mol/L lucigenin, and 1 mmol/L NADH or NADPH.
Luminescence was calculated as the rate of counts per mg protein
after deduction of the counts obtained from a buffer blank.
Detection of Vascular O2 by Lucigenin-
Enhanced Chemiluminescence
Aortic segments were prepared as described above. Approximately
5-mm-long rings were transferred into tubes containing HEPES
buffer and incubated at 37°C for 30 minutes before addition of 5
mol/L of lucigenin. Luminescence was measured as above.
Statistical Analysis
Data are expressed as meanSEM. Numbers (n) indicated through-
out the article denote the number of animals used in vascular
reactivity studies or enzymatic assays. Dose-response curves were
fitted by nonlinear regression with simplex algorithm. Relaxant
responses were given as the percentages of PE precontraction.
Comparisons of dose-response curves were evaluated by 2-way
ANOVA for repeated measures. Probability values 0.05 were
considered to be statistically significant.
Results
General Data
The systolic blood pressure and the heart weight/body weight
ratio were significantly higher in SHR compared with WKY.
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However, there was no significant difference in body weight
or basal heart rate between the 2 groups (Table 1).
Levels of eNOS and NAD(P)H Oxidase Activity
and NO and O2 in WKY and SHR Aorta Before
and After Treatments With Vitamins C and E
The activities of eNOS and NAD(P)H oxidase were found to
be significantly higher in SHR aortic homogenates before
treatments with either vitamin. However, the treatments with
vitamin C (any dose used between 10 and 100 mol/L) and
higher concentrations of vitamin E (100 mol/L) decreased
NAD(P)H oxidase activity and O2 production but increased
eNOS activity and NO generation to the levels observed in
vitamin C- and E-treated WKY aortas (Table 2).
Enzymatic and Cellular Sources of O2 in WKY
and SHR Aorta
Endothelial NOS activity was abrogated in SHR and WKY
aortas through mechanical and pharmacological removal of
the endothelium by rubbing and incubation with N-nitro-L-
arginine methyl ester (L-NAME, 100 mol/L) for 1 hour
before quantification of O2 levels. Although the mechanical
removal of endothelium significantly reduced the basal level
of O2 in both strains, the decrease was not significant in
response to treatments with L-NAME in either strain (Table 3).
In contrast, the treatment of SHR aortas with 2 different
inhibitors of NAD(P)H oxidase, namely apocynin and diphe-
nyleneiodinium (DPI,10 and 100 mol/L), elicited a signifi-
cant reduction in O2 production in a dose-dependent manner,
indicating this enzyme as the main source of vascular O2
(Table 3).
Vasodilator Responses in Thoracic Aorta
In PE-precontracted aortic rings, although ACh produced a
concentration-dependent relaxation in WKY, it generated
contractile responses in SHR at higher doses, indicating a
defect in vascular endothelium (Figure 1A). There was no
difference in the relaxant responses of SHR and WKY rings
to incremental concentrations of SNP, an endothelium-
independent relaxant (Figure 1B).
Effects of Vitamins C and E on Vasodilation
To determine whether antioxidant vitamins potentiate the
vasodilatory effects of ACh in SHR and WKY aortas, the
rings from both species were treated with 4 different concen-
trations of these vitamins (10, 25, 50, and 100 mol/L) for 20
minutes before investigation of relaxant responses. All con-
centrations of vitamin C elicited significant relaxation in SHR
rings compared with WKY (Figure 2). In contrast, only the
highest concentration of vitamin E (100 mol/L) improved
endothelial function in SHR suggesting a dose-dependency
for the beneficial effects of vitamin E (Figure 3).
Discussion
The major conclusions to be drawn from this study are that
the antioxidant properties of vitamins C and E are associated
with decreased activation of NAD(P)H oxidase and hence
generation of O2 and enhanced activation of eNOS and
therefore generation of NO. These findings provide crucial
TABLE 1. Biological Variables in 20–22-Week-Old SHR
Compared With WKY
Biological Parameters SHR WKY
Heart weight/body weight, mg/g 3.630.21* 3.100.18
Systolic blood pressure, mm Hg 18813* 14011
Body weight, g 39839 38726
Basal heart rate, bpm 25719 24428
Data are meanSEM (n30).
*P0.05.
TABLE 2. Levels of eNOS and NAD(P)H Oxidase Activity and Nitrite and O2 in WKY and SHR Aortas Before and After Treatments
With 100 mol/L Vitamin C and E
Group
eNOS Activity
(pmol L-citrulline/min/mg protein)
Nitrite Levels
(nmol/mg protein)
NADPH Oxidase
(counts/min/mg protein)
NADH Oxidase
(counts/min/mg protein)
O2 Levels
(counts/min/mg protein)
SHR 0.380.08*† 8.850.60*† 4350280*† 42030*† 32018*†
WKY 0.150.04 5.700.80 2100220 21520 18025
SHRvit C 0.820.06 13.901.30 1520178 15218 16930
WKYvit C 0.750.08 13.301.10 1740135 18316 16119
SHRvit E 0.730.09 11.200.65 1690120 17925 18722
WKYvit E 0.710.05 11.750.95 1785190 19534 16317
Data are meanSEM (n6 for each group of rats).
*P0.05, difference within each group. Vitamin C or E-treated vs untreated. †P0.05, difference between 2 groups, SHR vs WKY.
TABLE 3. Effect of Inhibition of NOS, NAD(P)H Oxidase, and
Endothelium Denudation on O2 Production
Group n
O2 Production
(counts/min/mg protein)
SHR 6 32018†
WKY 6 18025
SHR100 mol/L L-NAME 4 26533
WKY100 mol/L L-NAME 4 15617
SHREndothelium denudation 4 20329*†
WKYEndothelium denudation 4 11123*
SHR10 mol/L DPI 4 15334*
SHR100 mol/L DPI 4 7919*
SHR10 mol/L Apocynin 4 12632*
SHR100 mol/L Apocynin 4 539*
Data are meanSEM. DPI indicates diphenyleneiodinium; L-NAME, Nw-nitro-
L-arginine methyl ester.
*P0.05, difference between basal and treatment groups within each strain;
†P0.05, difference between 2 groups, SHR vs WKY.
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evidence as to how antioxidant vitamins C and E may
improve vascular endothelial function in addition to their
well-established free radical–scavenging effects.
Vitamins C and E, along with the other low-molecular-
weight antioxidants such as urate and thiols, constitute the
first line of defense against oxidative stress in the extracel-
lular environment.25 These antioxidants prevent oxidation of
proteins and lipids by scavenging free oxygen radicals at the
expense of being consumed in the process.25 It is therefore
plausible to suggest that the levels of these antioxidants may
reflect the severity of resistance to oxidative stress. A close
association between the alleviation of hypertension and treat-
ments with these vitamins has been shown in experimental
models of hypertension, including SHR and salt-loaded
SHRSP.18,23 A consistent beneficial effect of vitamin C has
been reported in human subjects in that acute intra-arterial
administration of vitamin C to patients with diabetes mellitus
improves endothelium-dependent vascular relaxation.26 Sim-
ilarly, physiological and supraphysiological concentrations of
vitamin C have been shown to reverse endothelial dysfunc-
tion in conduit arteries of patients with congestive heart
failure and hypertension, respectively.27,28 However, clinical
data pertaining to beneficial effects of vitamin E have been
mixed. A randomized study, the Cambridge Heart Antioxi-
dant Study (CHAOS), revealed a marked reduction in non-
fatal myocardial infarction in patients randomly assigned to
treatment with 400 to 800 IU of vitamin E per day compared
with patients receiving placebo.20 Nevertheless, several sub-
sequent studies including the Heart Outcomes Prevention
Evaluation (HOPE) study have failed to confirm these
findings.29
In the present study, vitamin C (10 to 100 mol/L) and
high concentrations of vitamin E (100 mol/L) improved
endothelial function in the thoracic aortas of 20- to 22-week-
old male SHR to the levels that were observed in matching
normotensive WKY. Putative mechanisms whereby antioxi-
dant vitamins improve endothelial function may be due to (1)
their direct free radical–scavenging ability; (2) their ability to
regulate NO synthases that generate NO; (3) their ability to
regulate enzymes such as NAD(P)H oxidase that generate
free radicals; or (4) their ability to regulate antioxidant
enzymes, including superoxide dismutases (SODs), which
metabolize free radicals. The free radical–scavenging effects
of antioxidant vitamins are well documented.25 The beneficial
effects of dietary supplementation of vitamins C and E with
regard to reduction of blood pressure has also been well
documented in SHRSP and DOCA-salt hypertensive rats,
respectively.30,31 A recent study has linked these effects to the
regulation of enzyme systems that generate free radicals such
as NAD(P)H oxidase and SODs in vitamin C- and E-treated
SHRSP mesenteric arteries, which contribute to peripheral
resistance and blood pressure regulation significantly.18 How-
ever, the current data as to regulation of eNOS in SHR
cardiovascular system are contradictory, as increased, de-
creased, and unaltered levels of eNOS expression/activity
have been reported.11–13
In the present study, we investigated the levels of eNOS
activity and NO release in SHR thoracic aortas before and
Figure 1. Acetylcholine-induced (A) and SNP-induced (B) relax-
ation of phenylephrine-precontracted SHR and WKY aortic
rings. Results are expressed as meanSEM from 10 separate
experiments. *P0.01 SHR vs WKY.
Figure 2. A and B, Acetylcholine-induced relaxation in WKY and
SHR thoracic aorta, in the absence and presence of 10 mol/L
and 100 mol/L vitamin C. Results are expressed as
meanSEM from 10 separate experiments. *P0.01 SHR vs
WKY, †P0.01 compared with relaxation in the presence of
vitamin C.
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after treatments with antioxidant vitamins C and E compared
with WKY. We revealed that treatments with different
concentrations of vitamin C (10 to 100 mol/L) and higher
doses of vitamin E (100 mol/L) lead to an increase in both
eNOS activity and NO levels in both SHR and WKY aortas,
which were in keeping with the previous studies also showing
increases in NOS activity and NO generation in SHR arter-
ies.22,32 Although higher percent increases in NOS activity
and NO production have been observed in WKY aortas after
treatments with vitamins C and E, the basal release of NO
was found to be 2-fold greater in SHR aortas, suggesting that
the endothelial dysfunction in SHR aortas could not be due to
the blunted NOS responses. This was further verified by the
demonstration of almost 2-fold increase in basal NOS activity
in SHR aortas.
The present study confirmed the presence of endothelial
dysfunction in SHR aortas by use of ACh, which produced
relaxant responses in WKY aortas in a dose-dependent
manner but elicited vasoconstriction in SHR aorta at high
doses, suggesting the stimulation of the muscarinic receptors
on vascular smooth muscle as a consequence of a defect in
vascular endothelium.33 On the other hand, SNP, an endothe-
lium-independent relaxant, produced the same degree of
vasorelaxation in the thoracic aortas of both strain.
This study has also shown an enhanced generation of O2
and activation of NAD(P)H oxidase enzyme system in
untreated SHR aortas. NAD(P)H oxidase has recently been
characterized in several cell lines and shown to be one of the
main source of vascular O2, along with the uncoupled state
of eNOS.34,35 However, treatments of SHR aortas with
different concentrations of vitamin C (10 to 100 mol/L) and
higher concentrations of vitamin E (100 mol/L) diminished
generation of O2 and activation of NAD(P)H oxidase in SHR
aortic homogenates, suggesting a vascular protective role for
both of these vitamins provided that an adequate dose is
chosen, particularly in case of vitamin E. To determine the
contribution of eNOS to vascular O2 production, we re-
moved endothelium from vessels by rubbing or by incubating
with an eNOS inhibitor, L-NAME. The mechanical removal
of endothelium significantly but not fully reduced the basal
level of O2 in both SHR and WKY aortas, thereby suggest-
ing that vascular smooth muscle cells and adventitial fibro-
blasts may be alternative sources of O2 generation. However,
the decrease in the O2 was not significant in response to
treatments with L-NAME in both strains, indicating
NAD(P)H oxidase as the main source of O2 in SHR at 20 to
22 weeks age, the well-established hypertensive stage. To
further verify this hypothesis, we treated SHR aortas with
specific inhibitors of NAD(P)H oxidase, for example, apoc-
ynin and DPI, and showed that both inhibitors reduced O2
production significantly in a dose-dependent manner (Table 3).
Although this study did not investigate either vascular
SOD activity or total antioxidant status, a previous study
showed significant elevations in both of these parameters in
another model of genetic hypertension, salt-loaded SHRSP.22
The mechanisms by which vitamins C and E may modulate
NAD(P)H oxidase or eNOS activities are unclear; it has been
suggested that vitamins may be involved in both the tran-
scription and posttranslational modification of NAD(P)H
oxidase36 and perhaps eNOS. Vitamin E, a lipophilic antiox-
idant,36 may modulate the interactions between cytochrome
b558, the membrane-bound part of NAD(P)H oxidase en-
zyme that is required for enzyme activity and stability as a
whole, and the cytosolic components of this enzyme system
that translocate to the plasma membrane on activation.
Moreover, vitamin E is taken up by LDL particles and
therefore improves endothelial function by reducing the
sensitivity of LDL to in vitro oxidation in healthy subjects as
well as type 2 diabetics.37 However, other studies have shown
that in vitro or in vivo enrichment of LDL with -tocopherol
accelerates rather than inhibits LDL oxidation if there is a
shortage of other antioxidants including vitamin C in the
environment.38 This suggests that vitamin C may mediate
some of its functions through vitamin E. Vitamin C, in
addition to its direct ROS-scavenging effects, may also have
other beneficial effects as the result of its ability to increase
the availability of the eNOS cofactor H4B, thereby enhancing
eNOS activity.39
Data from this study confirm the involvement of oxidative
stress in the pathogenesis of genetic endothelial dysfunction
and indicate a requirement for a relatively higher dose of
vitamin E compared with vitamin C to improve vascular
relaxation. It also sheds some light as to why discrepant
results have been reported in response to treatments with
vitamin E.
We have demonstrated in the present study that treatment
with vitamins C and high doses of vitamin E reverse impaired
endothelium-dependent vascular relaxation in a genetic
Figure 3. A and B, Acetylcholine-induced relaxation in WKY and
SHR thoracic aorta, in the absence and presence of 10 mol/L
and 100 mol/L vitamin E. Results are expressed as
meanSEM from 10 separate experiments. *P0.01 SHR vs
WKY, †P0.01 compared with relaxation in the presence of
vitamin E.
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model of human essential hypertension. These effects are
associated with enhanced generation of NO and activity of
eNOS as well as diminished production of O2 and activity of
NAD(P)H oxidase. These findings provide important evi-
dence for the use of adequate levels of antioxidant vitamins C
and E in the treatments of pathologies that are associated with
oxidative stress.
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